US Patent 7531532 Pyridine derivative and pyrimidine derivative
Patent 7531532 was granted and assigned to Eisai (company) on May, 2009 by the United States Patent and Trademark Office.
All edits
Edits on 15 Sep, 2023
Golden AI
Edits made to:
Article (+297 characters)
Article
Patent abstract
A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity.
Edits on 14 Jul, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07531532 Pyridine derivative and pyrimidine derivative US Patent 7531532 Pyridine derivative and pyrimidine derivative
Infobox
Patent Number
0753153200
Patent Number
753153200
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 22 Mar, 2023
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
075315320
Date of Patent
May 12, 2009
0Patent Application Number
110656310
Date Filed
February 25, 2005
0Official Website
Patent Primary Examiner
Edits on 26 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
075315320
Date of Patent
May 12, 2009
0Patent Application Number
110656310
Date Filed
February 25, 2005
0Official Website
Patent Primary Examiner
Edits on 15 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 2 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07531532 Pyridine derivative and pyrimidine derivative
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07531532
Date of patent
May 12, 2009
Patent application number
11065631
Date Filed
February 25, 2005
Patent primary examiner
Find more entities like US Patent 7531532 Pyridine derivative and pyrimidine derivative
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.